Mehrdad Solati
1*, Hamid-Reza Mahboobi
21 Department of Endocrinology and Metabolism, Hormozgan University of Medical sciences, Hormozgan, Iran.
2 Behavioral and Neurosciences Research Center, Hormozgan University of Medical sciences, Hormozgan, Iran.
*Corresponding Author: *Corresponding author: Dr. Mehrdad Solati, Department of Endocrinology and Metabolism, Hormozgan University of Medical Sciences, Hormozgan, Iran. Telephone: +98 761 6668164, Fax: +98 761 6668 427,, Email:
mehrdadsol@hotmail.com
Implication for health policy/practice/research/medical education:
Recent studies have focused on decrease activity of paraoxonase (PON) in chronic kidney disease (CKD) patients. Paraoxonase (PON) enzyme is altered in many diseases and is related to lipid abnormalities and antioxidant activities. Patients with CKD often have lipid abnormalities. Lipid abnormalities in CKD patients increase the risk of cardiovascular diseases in CKD patients. In CKD patients, PON activity and its mechanism have developed a new idea for treatment options to reduce the risk of cardiovascular disease. This review article is focused on the role of PON in dyslipidemia in the CKD patients.
Please cite this paper as: Solati M, Mahboobi HR. Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients. . J Nephropathology. 2012; 1(3): 123-125. DOI: 10.5812/nephropathol.8106